{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AZD6244&page=2", "query": { "intervention": "AZD6244", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AZD6244&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T18:49:20.600Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01217450", "title": "Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-10", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-29", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Madison, Wisconsin • Milwaukee, Wisconsin", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217450" }, { "nct_id": "NCT01011933", "title": "Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2009-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 72, "location_summary": "Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 44 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01011933" }, { "nct_id": "NCT03649165", "title": "A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)", "Healthy Participants" ], "interventions": [ { "name": "Treatment A", "type": "DRUG" }, { "name": "Treatment B", "type": "DRUG" }, { "name": "Treatment C", "type": "DRUG" }, { "name": "Treatment D", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 24, "start_date": "2018-09-05", "completion_date": "2018-10-21", "has_results": false, "last_update_posted_date": "2018-11-08", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03649165" }, { "nct_id": "NCT00553332", "title": "Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver and Intrahepatic Biliary Tract Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Unresectable Extrahepatic Bile Duct Cancer" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-11", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2016-04-22", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 7, "location_summary": "Tampa, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00553332" }, { "nct_id": "NCT03259633", "title": "An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "NF type1 With Inoperable Plexiform Neurofibromas" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "2 Years to 130 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2020-05-01", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03259633" }, { "nct_id": "NCT00780676", "title": "Personalized Treatment Selection for Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "AZD6244", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 97, "start_date": "2009-06", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00780676" }, { "nct_id": "NCT01143402", "title": "Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iris Melanoma", "Medium/Large Size Posterior Uveal Melanoma", "Ocular Melanoma With Extraocular Extension", "Recurrent Uveal Melanoma", "Small Size Posterior Uveal Melanoma", "Stage IV Uveal Melanoma" ], "interventions": [ { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-06", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 32, "location_summary": "Aurora, Colorado • Miami Beach, Florida • Tampa, Florida + 25 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01143402" }, { "nct_id": "NCT00600496", "title": "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Breast Neoplasms", "Colon Cancer", "Colonic Cancer", "Colon Neoplasms", "Lung Cancer", "Melanoma", "Kidney Cancer" ], "interventions": [ { "name": "AZD6244", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 140, "start_date": "2007-12-14", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 4, "location_summary": "Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600496" }, { "nct_id": "NCT03833427", "title": "Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-03-18", "completion_date": "2022-06-28", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 4, "location_summary": "Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03833427" }, { "nct_id": "NCT00551070", "title": "Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Ovarian Serous Tumor", "Low Grade Ovarian Serous Adenocarcinoma", "Micropapillary Serous Carcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Low Grade Serous Adenocarcinoma", "Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2007-12-17", "completion_date": "2020-11-13", "has_results": true, "last_update_posted_date": "2020-12-03", "last_synced_at": "2026-09-24T18:49:20.600Z", "location_count": 49, "location_summary": "Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 32 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551070" } ] }